home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408e.zip
/
M9480828.TXT
< prev
next >
Wrap
Text File
|
1994-09-05
|
2KB
|
34 lines
Document 0828
DOCN M9480828
TI Antigen clearance for evaluation of treatment of histoplasmosis.
DT 9410
AU Blair R; Garringer T; Limjoco M; Korzun A; Hafner R; Wheat J; Indiana
University, Indianapolis.
SO Abstr Gen Meet Am Soc Microbiol. 1994;94:605 (abstract no. F-95). Unique
Identifier : AIDSLINE ASM94/94313117
AB Evaluation of new antifungal agents may be assisted by measurement of
Histoplasma antigen clearance. We compared antigen clearance in patients
treated successfully with itraconazole to that in historical controls
treated with amphotericin B. Patients receiving itra were participants
in an AIDS Clinical Trials Group protocol. The historical control group
included AIDS patients treated with ampho B from 1988 to 1992. Antigen
clearance was measured by radioimmunoassay, testing samples at baseline
and at the end of induction treatment in a single assay to allow direct
comparison. Antigenuria cleared more rapidly in patients treated with
ampho B than with itra. TABULAR DATA, SEE ABSTRACT VOLUME. Antigenemia
clearance was similar in both groups. This rate of clearance of antigen
correlates with clinical evidence of more rapid response to treatment
with ampho B than itra, namely defervescence. Clearance of antigen may
complement clinical and cultural markers for evaluation of antifungal
therapy for histoplasmosis.
DE Acquired Immunodeficiency Syndrome/THERAPY Amphotericin B/*THERAPEUTIC
USE Antigens, Fungal/*BLOOD/URINE AIDS-Related Opportunistic
Infections/*PREVENTION & CONTROL Comparative Study
Histoplasma/*IMMUNOLOGY Histoplasmosis/*PREVENTION & CONTROL Human
Itraconazole/*THERAPEUTIC USE Metabolic Clearance Rate CLINICAL TRIAL
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).